

BUSINESS NEWS UPDATES

UPDATED
Thursday, 2:17 PM
From the Boston Globe Business Team

Organogenesis will study combat injury treatments

April 17, 2008 02:17 PM



[Organogenesis Inc.](#), a Canton biotechnology company that makes artificial skin, said today that it is part of a large consortium that aims to develop regenerative medicine therapies to treat battlefield injuries.

The consortium is led by the [Institute for Regenerative Medicine at Wake Forest University's Baptist Medical Center](#), and it will be awarded \$42.5 million over five years by the [US Army Institute of Surgical Research](#), Organogenesis said.

Organogenesis chief executive Geoff MacKay (left) said in a statement that he believed his company's experience in regenerative medicine technology will be beneficial to the consortium.

For recent Globe coverage of Organogenesis, click [here](#).
(By Chris Reidy, Globe staff)